20191218 Financial calendar 2020 EN
Category: 2019
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
20191212 PR TG4010_EN_results
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
20191211 PR preclinical BT001 EN
Transgene Announces Investor Meetings for January 2020
20191209 PR Investors Meeting agenda 2020
Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
20191114 Résultats T3-2019 EN
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download the poster here Poster Presentation
Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
20191022 – Transgene PR Jefferies EN
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
20190930 PR TG4001 ESMO EN
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
20190918-Transgene-H1-2019-RESULTS-EN
